Dr. Suzanne Turner
|Research Topic||Paediatric lymphoma and neuroblastoma|
|Research Interest||Suzanne D. Turner, PhD is a Senior Lecturer in tumour biology and pathology at the University of Cambridge. She directs a research group investigating mechanisms of ALK-induced malignancies and has contributed significantly to our understanding of the carcinogenic process having created one of the first murine models of ALK-induced tumour formation. In particular, mechanisms relating to the role of the T cell receptor in ALK-induced lymphomagenesis are an interest of the Turner group.|
|Contact||Division of Molecular Histopathology
Lab Block Level 3, Box 231
Cambridge, CB2 0QQ, UK
Telephone: +44 (0)1223 762655
Dr. Olaf Merkel
Medical University Vienna
|Research Topic||Molecular profiling and apoptosis regulation in lymphoma|
|Research Interest||Olaf Merkel is a lecturer in cancer therapeutics and an experienced biochemist. His main research interests are B and T-cell lymphomas. The focus of his group are non-coding RNAs, in particular miRNA and their impact on oncogenesis and cell survival. In particular, he is interested in the role of the oncogenic miR-155 and miR-17-92 clusters. Moreover, recently he became interested in cytokine regulation by BATF and cJUN in T-cell lymphomas. Also how cytokine signals are then transduced to the nucleus by the JAK/STAT pathway. Kinases in this pathway are potential therapeutic targets.|
|Contact||Clinical Institute for Pathology
Medical University of Vienna
Währinger Gürtel,18-20, A-1090 Vienna, Austria
Phone: +43 1 4040036610
Dr. Gerda Egger
Medical University of Vienna
|Research Topic||Epigenetics of ALK dependent cancers|
|Research Interest||Gerda Egger is lecturer on epigenetics and tumour biology since 2009. She directs a research group studying the impact of epigenetics in different diseases including cancer. Using mouse models we are trying to understand how epigenetic aberrations are generated and how they can be reversed and remodelled. We are using genome-scale analyses to define targets of differential DNA methylation in patient samples to define epigenetic biomarkers and to discover epigenetic drivers of different pathologies.|
|Contact||Clinical Institute of Pathology
Währinger Gürtel 18-20
1090 Vienna, Austria
Phone: +43 1 40400 63890
Prof. Lukas Kenner
|Research Topic||AP-1 in Lymphoma formation|
Lukas Kenner is board certified pathologist and an internationally acknowledged expert in comparative pathology. His research interest is the exploration of molecular mechanisms in neoplastic disease, their functional relevance for tumor progression and potential for clinical i8mprovements through diagnostic and prognostic measures. He has generated several transgenic mouse models for investigating the roles of AP-1 and PDGFRB in NPM-ALK transgenic mice.
|Contact||Ludwig Boltzmann Institute for Cancer Research (LBI-CR)
phone: +43 1 427764111
Prof. Šárka Pospíšilová,
|Research Topic||Genomics of lymphoproliferative disorders; role of p53 abnormalities in cancer|
|Research Interest||Prof. S. Pospisilova is head of the research center of Molecular Medicine in CEITEC, MU and also works in the department of Internal Medicine – Hematology and Oncology in the University Hospital Brno. She coordinates national and international research projects in leukaemia and lymphoma and is a member of the board of the European Research Initiative on CLL (ERIC) within the European Leukaemia Net. Her research group studies the genomic background of ALK-related malignancies (with application of NGS and array technologies) and the role of the p53 pathway and microRNAs in these tumours.
Characterization of ALK role in paediatric tumours specifically in neuroblastoma and rhabdomyosarcoma. Introduction of high-throughput analyses of human genomes for diagnostic tests.Study of neuroblastoma and other paediatric CNV (copy number variation) malignancies as epigenetic diseases with aim to better understand role of epigenome in ALK-induced malignancies in general. Identification of potential therapeutic targets in relapsed or refractory paediatric malignancies applicable in clinical practice.
|Publications||Publication Link (SP)|
Brno – Bohunice 625 00, Czech Republic
Prof. Falko Fend,
|Research Topic||Molecular Hematopathology|
|Research Interest||Prof. Falko Fend is head of the Department of Pathology and has a long track record in lymphoma research, molecular pathology and as a diagnostic hematopathologist. Prof. Quintanilla-Martinez de Fend, senior staff member and group leader, is a renowned hematopathologist with a long track record in lymphoma research and is an active leading member of international societies and groups in the field. Our research interests include the pathobiology of ALCL, genetics of early stages of lymphoma and the advancement of molecular diagnostics in hematopathology.|
|Publications||Publication Link (FF)|
|Contact||Institute of Pathology and Neuropathology
University Hospital Tuebingen
72076 Tuebingen, Germany
Prof. Carlo Gambacorti Passerini
|Research Topic||Clinical research into disease mechanisms of neoplastic disease|
Prof. Carlo Gambacorti-Passerini is a leading physician in the field of oncogenic fusion proteins and tyrosine kinase inhibitors. He has contributed significantly to the development of imatinib for the treatment of CML and successfully pioneered an ALK+ lymphoma patient therapy with ALK inhibitors. His research centers on identifying the molecular pathogenesis of hematological cancers using genome sequencing. He is interested in molecular mechanisms governing the transition from chronic phase to blast crisis in CML. In addition he is engaged in target validation of oncogenic fusion genes, structural characterization and screening of small-molecule inhibitors and new tyrosine kinase inhibitors to overcome therapy resistance in patients with ALK+ lymphomas.
|Contact||Via Pergolesi 33
20900 Monza, Italy
Phone: 0039 0392339553
Dr. Sylvie Giuriato
The Cancer Research Centre of Toulouse (CRCT)
|Research Topic||RNA biology in hematological cancers|
|Research Interest||Dr Sylvie Giuriato has focused recently on the role of autophagy following crizotinib therapy in ALK-positive ALCL. The goal is to pursue understanding the role and the regulation (in particular post-transcriptional regulation through microRNAs and/or RNA-Binding proteins) of this process in different ALK-positive tumours, both in basal conditions and following targeted-, chemo- and immuno-therapies.|
|Contact||UMR1037 INSERM-UPS-ERL5294 CNRS
Team 7: RNA biology in hematological cancers
Oncopole de Toulouse, Entrée C,
2 avenue Hubert Curien
31037 TOULOUSE Cedex 1 – FRANCE
Dr. Stephan Mathas
|Research Topic||Mechanisms of transformation in lymphoma|
|Research Interest||Stephan Mathas works as an MD treating in particular patients suffering from malignant lymphomas and group leader at the Max-Delbrück-Centre for Molecular Medicine. His research focuses on the pathogenesis of classical Hodgkin lymphoma and ALCL, for which his laboratory has already identified key molecular defects.|
|Contact||Institute for Hematology, Oncology and Tumorimmunology
Charité University Medical School
13353 Berlin, Germany
Phone: 0049 30 94 06 – 28 63
Dr. Roberto Chiarle
University of Torino
|Research Topic||In vivo models of ALK-driven tumors and ALK-targeted immunotherapy|
Roberto Chiarle has wide expertise in cellular biology, immunology, and molecular biology. He holds clinical qualifications for haematopathology and is currently the recipient of a double appointment as Full Professor and clinical physician at the University of Torino and as Associate Professor at Harvard Medical School. RC is a pioneer in the field of ALK-related lymphoma having generated one of the first mouse models of ALK-induced ALCL. His research aims at therapeutic targeting of ALK by means of specific inhibitors, drugs and immunotherapy. His objectives are therefore to improve our understanding of the molecular mechanisms of
|Contact||Department of Molecular Biotechnology and Health Sciences
University of Torino
Via Santena, 7 – 10126 Torino, ITALY
Phone: +39 011.633.6861
Prof. Wilhelm Woessmann,
|Research Topic||Molecular diagnosis of childhood ALCL; Immune response to ALK in ALCL|
|Research Interest||Wilhelm Woessmann is a paediatric oncologist, co-chair of the NHL-BFM study group and an active member of the European paediatric NHL study group (EICNHL). His translational research includes biological risk factors, molecular biology and immune response against ALK in children with ALCL.|
Dept of Pediatric Hematology and Oncology
Phone: +49- (0) 641-985-43462 or -43400
Dr. Laurence Brugieres,
|Research Topic||Immunology of ALCL|
|Research Interest||Laurence Brugieres, MD is a paediatric oncologist involved in ALCL trials since 1999. She is engaged in a research programme devoted to biological mechanisms involved in immunogenicity of ALCL in children and investigates immune responses against ALK according to the type of treatment given to the patients.|
|Contact||Maison du projet
39, rue Camille Desmoulins
94 800 Villejuif
Phone: + 33 (0)1 42 11 50 05
Prof. Bengt Hallberg,
|Research Topic||Mechanisms behind the oncogene ALK in cell and mouse model systems|
|Research Interest||Bengt Hallberg has been working with receptor tyrosine kinase-mediated signalling since the beginning of the 1990’s. Recently his research has been addressing the role of ALK in the pathogenesis of neuroblastoma and has shown a dependence on ALK for MYCN transcription. He is investigating the function and importance of ALK RTK’s and differences in constitutively active ALK RTK mediated signalling at the molecular level as compared with wild type ALK in relevant cell models. This work is also carried out in mouse models which we have developed in with the aim of addressing ALK signalling in vivo.
Ruth Palmer has been working with ALK in the fruitfly Drosophila melanogaster since 1996. The laboratory is investigating ALK signal transduction with an interest in its role in developmental processes employing Drosophila melanogaster and mouse model systems. Our aim is to understand the importance and function of the ALK receptor tyrosine kinase during both normal and pathological developmental process.
|Publications||Publication Link (BH)|
|Contact||Medicinaregatan 9 a
413 90, Göteborg
Phone: +46 31 7863815
Prof. Justus Duyster,
|Research Topic||Identification and Eradication of ALCL-Lymphoma Stem cells|
|Research Interest||Prof. Justus Duyster is head of Medical Clinic for Hematology, Oncology and stem cell transplantation and has a long track record in the field of lymphoma and leukemia research and oncogenic fusion proteins. The Duyster group has previously established a murine bone marrow transplantation model and showed that retroviral NPM-ALK transduction into murine bone marrow leads to a histocytic or plasmocytic disease depending on viral titre. To induce a T-lymhoid ALCL in mice, we currently expressed NPM-ALK in a spatio-temporal manner. We will use this model to study lymphoma stem cells in NPM-ALK driven lymphomas and the eradication of the Lymphoma initiating population. Moreover, our current research involves the signal-transduction and the crosstalk between the DNA-damage stress axis in lymphoma initiation and progression.|
|Publications||Publication Link (JD)|
|Contact||Prof. Dr. Justus Duyster/ Dr. Lena Illert
University Medical Center Freiburg
Dept. of Hematology, Oncology and Stem Cell Transplantation
Hugstetter Str. 55
79106 Freiburg, Germany
The Naked Scientists are a multi-award-winning initiative comprising a group of Cambridge University-based scientists and doctors who are also specialists in science communication techniques including radio broadcasts, podcasts, published books and online media. The team are supported by UK research councils and air science material live on radio networks internationally each week including across the UK (BBC 5 Live), Australia (ABC Radio National), South Africa (Primedia) and Europe (Talk Radio Europe). Their podcasts have been downloaded 30 million times in the last 4 years.
TissueGnostics was founded in April 2003 and has a proven track record in developing innovative and trend-setting products in the field of tissue cytometry. While flow cytometry is restricted to cells in suspension (e.g. blood) the tissue cytometers made by TG – termed “HistoFAXS” and “TissueFAXS” work with fixed material.
Roche Austria GmbH is one of Austria’s leading suppliers of pharmaceuticals. In 2013 the company employed approximately 650 people in Austria (Vienna and Graz). Roche leads the overall Austrian pharmaceutical market and is number one in the hospital market and in cancer drugs.
GALKEM SRL., created in 2013, is a University spinoff company devoted to finding new small molecule inhibitors of the ALK tyrosine kinase for the therapeutic targeting of crizotinib-resistant disease. In addition, GALKEM SRL. provides a Next Generation Sequencing service for academic partners. It offers a stimulating environment where industrial research is embedded in academic laboratories working at the interface of chemistry and biology.
Biolution is an experienced service provider for biotech and university clients alike; they are specialized in supporting consortia in the initiation and execution of EU funding programs. Biolution combines management experience and scientific expertise, providing the necessary skills to meet the challenges of EU projects. Over the past decade, Biolution has managed 9 projects within the FP6 and FP7 frameworks worth around €20 million.
Since its foundation in 2002, Biolution has become Austria´s premier service provider for the application, implementation, and management of research projects in the life sciences. They take pride in their high success rate and are proactively adapting services to the challenges of Horizon 2020.
In addition, Biolution regularly contributes to national science events and organises science communication activities for customers.
Varionostic is a spin-off company of the University (Hospital) of Ulm/Germany (founded 2006). Varionostic is Europe’s leading expert for DNA methylation analysis using the most up-to-date platforms of Pyrosequencing and MassARRAY. Varionostic offers outstanding tailored services ranging from assay design to data analysis to customers from industry and academia. Scientists can also profit from predesigned methylation assays developed within their own research facilities. Besides epigenetics, Varionostic also run genotyping and other DNA analytical projects.
The CESAR Central European Society for Anticancer Drug Research – EWIV is a European Non-Profit Organization aiming to foster research and development of novel anti-tumour agents, therapies and therapeutic strategies in oncology. CESAR comprises scientists from basic research, preclinical and clinical Oncology in Austria, Germany and Switzerland. Since 2005, the CESAR Central Office (CCO) has functioned as a “hub” for all clinical trials where CESAR is either participating via its network of clinical centres or in its capacity as Sponsor (Investigator-Initiated Trials – IITs). Quality and adherence to standards according to ICH-GCP are a top priority for CESAR.
Biobank Graz is the largest academic biobank in Europe and is a member of the newly formed European biobanking network BBRMI-ERIC and the Austrian network BBMRI.AT. Biobank Graz offers its services not only to scientists at the Medical University of Graz, but also to scientists from academia and industry worldwide. Due to its leading position in automation of collection and storage of samples, the maintenance of highest sample quality is one of its key features.
Cambridge Life Sciences are an in vitro diagnostic company specialising in autoimmune diseases; they develop, manufacture and distribute diagnostic test kits and reagents worldwide.
(ISO 13485:2003 and ISO 9001:2000 certified)
Sofigen was established as a spin-off company from Masaryk University (MU) focused on the development of molecular biological diagnostic approaches mainly for haematological and oncological diseases. One of their objectives is the application of high throughput genomics approaches to diagnostics and personalized medicine. The company was established in January 2013 and during its short history has successfully integrated into several collaborative research projects.